Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma

20 Apr 2021

Abstract excerpt

The immunomodulatory drug lenalidomide is used in patients with follicular lymphoma (FL) with the aim of stimulating T-cell antitumor immune response. However, little is known about the effects of lenalidomide on T-cell biology in vivo in patients with FL. We thus undertook an extensive longitudinal immunologic study, including phenotypic, transcriptomic, and functional analyses, on 44 first-line and 27...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33877296
DOI: 10.1182/bloodadvances.2020003774

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphomaPMID 33877296Read ↗

Distinct follicular T cell subsets regulate lymphoma progression and outcomesSemantic proximity Read ↗

An updated understanding of follicular lymphoma transformationSemantic proximity Read ↗

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.Semantic proximity Read ↗

Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic targetSemantic proximity Read ↗

Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphomaSemantic proximity Read ↗

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survivalSemantic proximity Read ↗

Hepatitis B Virus-Associated Follicular Lymphoma Reveals T-Cell Inflamed Phenotype and Response to LenalidomideSemantic proximity Read ↗

Pomalidomide enhances CAR-T cell therapeutic efficacy and Remodels Immune Microenvironment in Lymphoid MalignanciesSemantic proximity Read ↗

Lenalidomide enhances CD19 CAR-T cell fitness and target-cell engagement in relapsed/refractory CLLSemantic proximity Read ↗

Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphomaSemantic proximity Read ↗

Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.Semantic proximity Read ↗

Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.